Fulcrum Therapeutics Financials
| FULC Stock | USD 7.28 0.16 2.15% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0483 | 0.046 |
|
| |||||
| Current Ratio | 18.6 | 17.7111 |
|
|
The financial analysis of Fulcrum Therapeutics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Fulcrum Therapeutics includes many different criteria found on its balance sheet. For example, investors should never minimize Fulcrum Therapeutics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Fulcrum Therapeutics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Fulcrum Therapeutics.
Net Income |
|
With this module, you can analyze Fulcrum financials for your investing period. You should be able to track the changes in Fulcrum Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Fulcrum | Select Account or Indicator |
Understanding current and past Fulcrum Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Fulcrum Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Fulcrum Therapeutics' assets may result in an increase in income on the income statement.
The data published in Fulcrum Therapeutics' official financial statements usually reflect Fulcrum Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Fulcrum Therapeutics. For example, before you start analyzing numbers published by Fulcrum accountants, it's critical to develop an understanding of what Fulcrum Therapeutics' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Fulcrum Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fulcrum Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Fulcrum Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Fulcrum Therapeutics. Please utilize our Beneish M Score to check the likelihood of Fulcrum Therapeutics' management manipulating its earnings.
Fulcrum Therapeutics Stock Summary
Fulcrum Therapeutics competes with RAPT Therapeutics, Mirum Pharmaceuticals, BeyondSpring, Stoke Therapeutics, and Phathom Pharmaceuticals. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Fulcrum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US3596161097 |
| CUSIP | 359616109 |
| Location | Massachusetts; U.S.A |
| Business Address | 26 Landsdowne Street, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.fulcrumtx.com |
| Phone | 617 651 8851 |
| Currency | USD - US Dollar |
You should never invest in Fulcrum Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Fulcrum Stock, because this is throwing your money away. Analyzing the key information contained in Fulcrum Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Fulcrum Therapeutics Key Financial Ratios
Generally speaking, Fulcrum Therapeutics' financial ratios allow both analysts and investors to convert raw data from Fulcrum Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Fulcrum Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Fulcrum Therapeutics reports annually and quarterly.| Return On Equity | -0.45 | ||||
| Operating Margin | (32.14) % | ||||
| Price To Sales | 165.60 X |
Fulcrum Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 110.4M | 129.6M | 235M | 226.7M | 257.7M | 164.9M | |
| Other Current Liab | 5.9M | 7.7M | 74K | 9.6M | 8.7M | 5.2M | |
| Other Liab | 11.1M | 7.7M | 4.3M | 197K | 177.3K | 168.4K | |
| Net Tangible Assets | 87.2M | 95.2M | 211.5M | 198.9M | 228.8M | 240.2M | |
| Net Debt | (96.7M) | (57.0M) | (35.4M) | (21.7M) | (14.7M) | (15.5M) | |
| Retained Earnings | (150.8M) | (221.6M) | (302.5M) | (412.3M) | (509.7M) | (484.2M) | |
| Accounts Payable | 2.2M | 4.1M | 4.8M | 3.6M | 2.8M | 3.2M | |
| Cash | 96.7M | 57.1M | 35.4M | 35.1M | 25.6M | 36.9M | |
| Other Assets | 1.2M | 1.7M | 1.6M | 3.2M | 3.7M | 3.9M | |
| Net Receivables | 111K | 2.7M | 4.1M | 1.1M | 2.2M | 1.7M | |
| Capital Surpluse | 237.9M | 316.8M | 514.4M | 612.0M | 703.8M | 739.0M | |
| Inventory | 3.0M | (2.8M) | (473K) | (852K) | (766.8K) | (728.5K) | |
| Other Current Assets | 284K | 74K | 4.2M | 4.4M | 3.7M | 2.1M | |
| Total Liab | 23.3M | 34.4M | 23.5M | 27.7M | 22.5M | 22.7M | |
| Net Invested Capital | 87.2M | 95.2M | 211.5M | 198.9M | 235.2M | 136.8M | |
| Total Current Assets | 100.1M | 112.9M | 226.0M | 207.5M | 242.2M | 151.5M | |
| Net Working Capital | 87.9M | 92.8M | 206.8M | 190.8M | 228.5M | 137.5M | |
| Short Term Debt | 50K | 17K | 9.6M | 2.6M | 2.2M | 2.3M | |
| Common Stock | 23K | 28K | 41K | 52K | 62K | 35.0K | |
| Capital Stock | 23K | 28K | 41K | 52K | 62K | 40.7K |
Fulcrum Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Fulcrum Therapeutics's current stock value. Our valuation model uses many indicators to compare Fulcrum Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fulcrum Therapeutics competition to find correlations between indicators driving Fulcrum Therapeutics's intrinsic value. More Info.Fulcrum Therapeutics is one of the top stocks in return on equity category among related companies. It is rated # 2 in return on asset category among related companies . At present, Fulcrum Therapeutics' Return On Equity is projected to increase significantly based on the last few years of reporting.Comparative valuation analysis is a catch-all model that can be used if you cannot value Fulcrum Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Fulcrum Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Fulcrum Therapeutics' earnings, one of the primary drivers of an investment's value.Fulcrum Therapeutics Systematic Risk
Fulcrum Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Fulcrum Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Fulcrum Therapeutics correlated with the market. If Beta is less than 0 Fulcrum Therapeutics generally moves in the opposite direction as compared to the market. If Fulcrum Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Fulcrum Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Fulcrum Therapeutics is generally in the same direction as the market. If Beta > 1 Fulcrum Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About Fulcrum Therapeutics Financials
What exactly are Fulcrum Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Fulcrum Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Fulcrum Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Fulcrum Therapeutics investors may use each financial statement separately, they are all related. The changes in Fulcrum Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Fulcrum Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Fulcrum Therapeutics Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Fulcrum Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Fulcrum has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Fulcrum Therapeutics' financials are consistent with your investment objective using the following steps:- Review Fulcrum Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Fulcrum Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Fulcrum Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Fulcrum Therapeutics' stock is overvalued or undervalued.
Today, most investors in Fulcrum Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Fulcrum Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Fulcrum Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Fulcrum Therapeutics April 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Fulcrum Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Fulcrum Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Fulcrum Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Fulcrum Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Fulcrum Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.48 | |||
| Information Ratio | 0.0229 | |||
| Maximum Drawdown | 22.0 | |||
| Value At Risk | (5.44) | |||
| Potential Upside | 7.77 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Fulcrum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.272 | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.